IDIOPATHIC PULMONARY FIBROSIS (IPF)
PURETEC 301 | LYT-100-2025-301
Sponsor: Puretech Health
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF).
BI-0002 | BI 1493-0002
Sponsor: Boehringer Ingleheimer
A Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase IIa Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 765423 Administered Intravenously With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis.
PROGRESSIVE PULMONARY FIBROSIS (PPF)
MIST | AP01-007
Sponsor: Avalyn Pharma
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Interested in Learning More About Pulmonary Fibrosis Trials?
Submit your information and our team will follow up within 24–48 hours.
What Can I Expect if I Enroll?
If you are interested in learning more or enrolling, our staff will contact you within a few days.
There is no obligation, and your information will be kept confidential. Our staff will:
- Screen interested participants for eligibility in active clinical trials
- Determine whether you may qualify for participation
- Explain study details, including protocol, duration, and compensation (varies by study)
- Provide clear guidance on the study process from start to finish and answer any questions
- Communicate with your established physician, as appropriate, regarding your participation
- Patient enrollment and participation are voluntary and may be discontinued at any time
Patients enrolled in our clinical trials remain under the care of their established physician for routine healthcare.
Simply provide your contact information, and our staff will guide you through the next steps.